{"pmid":32278860,"title":"Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.","text":["Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.","Mult Scler Relat Disord","Carnero Contentti, Edgar","Correa, Jorge","32278860"],"journal":"Mult Scler Relat Disord","authors":["Carnero Contentti, Edgar","Correa, Jorge"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278860","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.msard.2020.102097","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663890921985409025,"score":7.9164424,"similar":[{"pmid":32241953,"title":"Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.","text":["Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.","The emergence of novel Coronavirus 2019 (COVID-19)(1) and the subsequent pandemic present a unique challenge to Neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).","Neurology","Brownlee, Wallace","Bourdette, Dennis","Broadley, Simon","Killestein, Joep","Ciccarelli, Olga","32241953"],"abstract":["The emergence of novel Coronavirus 2019 (COVID-19)(1) and the subsequent pandemic present a unique challenge to Neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD)."],"journal":"Neurology","authors":["Brownlee, Wallace","Bourdette, Dennis","Broadley, Simon","Killestein, Joep","Ciccarelli, Olga"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241953","week":"202014|Mar 30 - Apr 05","doi":"10.1212/WNL.0000000000009507","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663352135743438848,"score":156.98415},{"pmid":32037473,"title":"New coronavirus: new challenges for pediatricians.","text":["New coronavirus: new challenges for pediatricians.","World J Pediatr","Chen, Zhi-Min","Fu, Jun-Fen","Shu, Qiang","32037473"],"journal":"World J Pediatr","authors":["Chen, Zhi-Min","Fu, Jun-Fen","Shu, Qiang"],"date":"2020-02-11T11:00:00Z","year":2020,"_id":"32037473","week":"20207|Feb 10 - Feb 16","doi":"10.1007/s12519-020-00346-4","source":"PubMed","topics":["Diagnosis","Treatment","Prevention"],"weight":1,"_version_":1663352134707445760,"score":45.696022},{"pmid":32240283,"title":"An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19.","text":["An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19.","Ann Intern Med","Alexander, G Caleb","Stoller, Kenneth B","Haffajee, Rebecca L","Saloner, Brendan","32240283"],"journal":"Ann Intern Med","authors":["Alexander, G Caleb","Stoller, Kenneth B","Haffajee, Rebecca L","Saloner, Brendan"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240283","week":"202014|Mar 30 - Apr 05","doi":"10.7326/M20-1141","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135575666688,"score":45.34288},{"pmid":32224277,"title":"COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology.","text":["COVID-19 and Immunomodulator/Immunosuppressant Use in Dermatology.","J Am Acad Dermatol","Price, Kyla N","Frew, John W","Hsiao, Jennifer L","Shi, Vivian Y","32224277"],"journal":"J Am Acad Dermatol","authors":["Price, Kyla N","Frew, John W","Hsiao, Jennifer L","Shi, Vivian Y"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224277","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaad.2020.03.046","keywords":["COVID-19","biologics","coronavirus","immunomodulators","immunosuppressants","small molecules","viral immune response"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135290454016,"score":44.376945},{"pmid":32205350,"title":"Tilorone: A Broad-Spectrum Antiviral For Emerging Viruses.","text":["Tilorone: A Broad-Spectrum Antiviral For Emerging Viruses.","Tilorone is a 50-year-old synthetic small-molecule compound with antiviral activity that is proposed to induce interferon after oral administration. This drug is used as a broad-spectrum antiviral in several countries of the Russian Federation. We have recently described activity in vitro and in vivo against the Ebola Virus. After a broad screening of additional viruses, we now describe in vitro activity against Chikungunya virus (CHIK) and Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV).","Antimicrob Agents Chemother","Ekins, Sean","Madrid, Peter B","32205350"],"abstract":["Tilorone is a 50-year-old synthetic small-molecule compound with antiviral activity that is proposed to induce interferon after oral administration. This drug is used as a broad-spectrum antiviral in several countries of the Russian Federation. We have recently described activity in vitro and in vivo against the Ebola Virus. After a broad screening of additional viruses, we now describe in vitro activity against Chikungunya virus (CHIK) and Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)."],"journal":"Antimicrob Agents Chemother","authors":["Ekins, Sean","Madrid, Peter B"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205350","week":"202013|Mar 23 - Mar 29","doi":"10.1128/AAC.00440-20","source":"PubMed","locations":["Chikungunya","vivo"],"topics":["Treatment"],"weight":1,"e_drugs":["Tilorone"],"_version_":1663352133742755840,"score":43.732338}]}